Min Cui, PhD, is an Investment Partner at Bay City Capital and Managing Director of Decheng Capital (www.decheng.com). Dr. Cui joined Bay City Capital in 2006, and focuses on evaluating investment opportunities as well as its initiatives in China. Dr. Cui was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs approved by the FDA. Prior to that Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals. He served as the Chief Scientific Officer and Executive Vice President of Pan Pacific Pharmaceuticals from 1998 to 2002 and Chief Executive Officer and President of Hucon Biopharmaceuticals from 2003 to 2005.  In these positions, he led the discovery and development efforts of several key technologies in the fields of oncology, cardiology, and infections and inflammatory diseases. Dr. Cui is a member of the board of directors of GenturaDx. His investment portfolio also includes Ion Torrent Systems (acquired by Life Technologies), China Biologic Products (NASDAQ: CBPO), Epizyme and Sunesis Pharmaceuticals (NASDAQ: SNSS). Dr. Cui was also a co-founder of CNetwork, a San Francisco-based nonprofit organization dedicated to serving Chinese communities in North America. He received his PhD in Cancer Biology from Stanford University and his BS in Molecular Biology from Peking University.